abstract |
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and is a tumour necrosis factor receptor 1 antagonist which is a TNFR1 domain antibody (dAb). The invention also pertains to a TNFR1 domain antibody (dAb) monomer which binds the tumour necrosis factor receptor 1, as well as to a ligand which contains such a monomer. The invention also relates to a method of inhibiting signal transmission through the TNFR1 receptor using said antagonists. The invention also discloses nucleic acid which codes said antagonist, a vector containing said nucleic acid, a host cell containing said vector, a pharmaceutical composition containing said antagonist or said dAb monomer. ^ EFFECT: invention can be effective in treating inflammatory diseases (for example chronic inflammatory diseases). ^ 57 cl, 99 dwg, 14 tbl, 20 ex |